ORPHA:263508
COG1-CDG
Also known as: CDG syndrome type IIg · CDG-IIg · CDG2G · Carbohydrate deficient glycoprotein syndrome type IIg · Congenital disorder of glycosylation type 2g · Congenital disorder of glycosylation type IIg
Query health: suspect — Only one of 3 strategies returned hits (phrase).
Publications
38
39.4th percentile
Trials
0
Interventional, condition-specific
Researchers
209
Distinct authors in sample
Gene link
COG1
Definitive
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
COG1-CDG is an extremely rare form of CDG syndrome characterized clinically in the few cases reported to date by variable signs including microcephaly, growth retardation, psychomotor retardation and facial dysmorphism.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0012637
- MeSH:C535756
- OMIM:611209
- UMLS:C2931011
Additional Mondo synonyms (4)
COG1-congenital disorder of glycosylation · carbohydrate deficient glycoprotein syndrome type IIg · congenital disorder of glycosylation type 2g · congenital disorder of glycosylation type IIg
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.
- Gene identifiedPresent
Definitive — COG1
- LiteraturePresent
38 matched papers (23 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (COG1).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
38
38 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
38 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
23 in the last 10 years · medium confidence · 39.4th percentile (publications denominator)
Phrase hits: 38 · MeSH hits: 0
Who's working on it?
209
Distinct author names in 38 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Jaeken J9 papers · 2023
Department of Pediatrics, Centre for Metabolic Diseases, University Hospital Gasthuisberg, Leuven, Belgium.
Papers in Europe PMC - 02Freeze HH6 papers · 2024
Genetic Disease Program, Sanford Children's Health Research Center, Sanford-Burnham Medical Research Institute, La Jolla, California 92037, USA. hudson@sanfordburnham.org
Papers in Europe PMC - 03Matthijs G5 papers · 2013Papers in Europe PMC
- 04Ng BG4 papers · 2024
Human Genetics Program, Sanford Children's Health Research Center, La Jolla, CA, USA.
Papers in Europe PMC - 05Ferreira CR3 papers · 2024
Skeletal Genomics Unit, Metabolic Medicine Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA.
Papers in Europe PMC - 06Garozzo D3 papers · 2013Papers in Europe PMC
- 07Lupashin VV3 papers · 2020
Department of Physiology and Biophysics, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Papers in Europe PMC - 08Sturiale L3 papers · 2013Papers in Europe PMC
- 09Climer LK2 papers · 2018
College of Medicine, Physiology and Biophysics, UAMS, Little Rock, AR, USA.
Papers in Europe PMC - 10D'Souza Z2 papers · 2020
Department of Physiology and Biophysics, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
medium confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"COG1-CDG" OR "CDG syndrome type IIg" OR "CDG-IIg" OR "CDG2G" OR "Carbohydrate deficient glycoprotein syndrome type IIg" OR "Congenital disorder of glycosylation type 2g" OR "Congenital disorder of the glycosylation type 2g" OR "Congenital disorder of glycosylation type IIg" OR "Congenital disorder of the glycosylation type IIg" OR "COG1-congenital disorder of glycosylation" OR "COG1-congenital disorder of the glycosylation"
MeSH descriptor terms unioned into the query: Congenital disorder of glycosylation, type 2G
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"COG1-CDG" OR "CDG syndrome type IIg" OR "CDG-IIg" OR "CDG2G" OR "Carbohydrate deficient glycoprotein syndrome type IIg" OR "Congenital disorder of glycosylation type 2g" OR "Congenital disorder of the glycosylation type 2g" OR "Congenital disorder of glycosylation type IIg" OR "Congenital disorder of the glycosylation type IIg" OR "COG1-congenital disorder of glycosylation" OR "COG1-congenital disorder of the glycosylation" OR "Congenital disorder of glycosylation, type 2G" OR "COG1"
Recall-expansion terms: COG1
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: suspect — strategies attempted: phrase, mesh, recall-expansion; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is short or not clearly distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T11:23:02.619Z